Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | White Papers
Search Refinements

Drug Discovery & Development White Papers

View white papers from other Pharmaceutical sectors:
91-105 of 109 results
Identifying and Exploiting Opportunities for Pharmacogenetics and Other Predictive Factors
| By Exploristics
Exploristics offer practical analysis tools that are built on basic principles and allow the evaluation of opportunities for PGx. This evaluation can be performed before the initiation of an extensive and costly experiment.
Drug Research > Drug Discovery & Development > White Papers
Latin America Emerges as World Competitor for Global Trials Despite Tough Regulatory Environment
| By World Courier
This article examines the regulatory atmosphere that prevails throughout Latin America and considers options that can streamline the timely flow of clinical trial materials through the supply chain.
Drug Research > Drug Discovery & Development > White Papers
Live Cell Imaging of Drug Effects on Golgi Morpholgy Using the CELLview™ Cell Culture Dish
| By Greiner Bio-One
Fluorescent and time lapse microscopy, advantages of multiplex analysis and the Golgi apparatus. Please donwload this free white paper for more information.
Drug Research > Drug Discovery & Development > White Papers
Management and Analysis of Biomarker Data
| By Exploristics
There is great expectation in the Pharmaceutical Industry that the era of personalised medicine will deliver safer and more effective treatments (Jørgensen & Winther, 2009). This promise is made possible by the emergence of new technologies and data acquisition platforms that can generate enormous amounts of patient-level biomarker data to characterise biological processes and explain response to treatment.
Drug Research > Drug Discovery & Development > White Papers
Nonclinical Development of Biopharmaceuticals
| By MPI Research
Fifteen years ago, small molecules (chemically synthesised molecules designed to interact with a specific cellular receptor) represented the majority of pharmaceuticals under development. During the past ten years, however, the number of therapies being developed that fall into the broad category of biopharmaceuticals has exploded, and there are predictions that the majority of therapies developed in the next ten years will fall into this class.
Drug Research > Drug Discovery & Development > White Papers
Overcoming the Limitations of Chemical Structure
| By Cresset
Biological targets do not recognise a drug's structural make-up. They respond instead to the properties around the drug generated by the structure. We can now generate and compare these property fields and show how they alone eliminate the largest impediments to drug discovery – the time and cost of evaluating activity and the serendipity involved in jumping from one chemical class to another for resolving patent issues, biological cross-reactions, ADMET and alternative clinical applications.
Drug Research > Drug Discovery & Development > White Papers
Peptides to Non-Peptides: Leads from Structureless Virtual Screening
| By Cresset
FieldPrints™ and field-based overlays have shown themselves to be a robust method for locationg new leads for medicinal chemistry programs. Unlike docking protocols, no x-ray protein information is required and only 2D structures are needed for two or more ligands known to act at the same site. Thus, the technique is applicable to many classes of target for which no acceptable lead-finding solution currently exists because the technique is based on the surface properties of molecules.
Drug Research > Drug Discovery & Development > White Papers
Profiling Pharmaceuticals with Neuronal Network Cultures
| By NeuroProof
Our advanced combination of primary neuronal cell cultures on MEA neurochips and sophisticated methods of data analysis is a major step forward in target validation, which remains as one of the bottlenecks in drug discovery.
Drug Research > Drug Discovery & Development > White Papers
Protecting Sensitive Information in Life Sciences Organisations
| By Brainloop
Critical business processes in biotech companies involve highly confidential, important documents that need to be safely accessed by external partners and potential licensees. Find a new way to protect this confidential documents.
Drug Research > Drug Discovery & Development > White Papers
ProtoDynamic Therapy: A Novel Therapeutic Concept for Inflammation and Cancer
| By BioCis Pharma
The newly introduced term protodynamic can be defined as a proton-derived force that produces a change in a living cell. The basic idea is to transport hydrogen ions (H+ or protons) from the mildly acidic extracellular medium into the cell, which causes intracellular acidification. The protodynamic mode of action and the efficacy of cis-UCA in various models of inflammation and cancer will be briefly presented in this paper.
Drug Research > Drug Discovery & Development > White Papers
Seamless Life Sciences Collaboration
| By Brainloop
Speeding up your time to market: Seamless online collaboration in the biopharmaceutical industry
Drug Research > Drug Discovery & Development > White Papers
Taking the Lead in Developmental and Reproductive Toxicology with Nonhuman Primates
| By MPI Research
As current and future growth in the drug discovery and development arena focuses on biologics, the accomplished Developmental and Reproductive Toxicology (DART) team at MPI Research is ready to meet the study needs of its sponsors. Unlike small molecules, which are active in many species, biologics are species specific and, in most cases, nonhuman primates are the only appropriate choice for preclinical testing.
Drug Research > Drug Discovery & Development > White Papers
Taming China's Clinical Trial 'Dragon'
| By World Courier
With a population in excess of 1.3 billion and low technical costs, China is a highly attractive venue for clinical trials. In this article, current regulations and permit requirements are examined and a transportation case study is presented. Local solutions and important considerations for choosing appropriate "in country" service providers are also discussed.
Drug Research > Drug Discovery & Development > White Papers
The Informed Design and Validation of Quality of Life Questionnaires and Rating Scales Using Rasch Analysis
| By Exploristics
This free white paper describes how some of the additional outputs from Rasch analysis can provide information beyond that of a simple analysis of the QoL data during the creation and validation of a new instrument or to understand and quantify responses following a clinical study.
Drug Research > Drug Discovery & Development > White Papers
The MPI Research: Nonhuman Primate Reproductive Toxicity Program
| By MPI Research
As current and future growth in the drug discovery and development arena focuses on biologics, the accomplished developmental and reproductive toxicology (DART) team at MPI Research is ready to meet the study needs of its sponsors.
Drug Research > Drug Discovery & Development > White Papers
91-105 of 109 results